The review summarizes information pertaining to the preclinical development of new apolipoprotein (apo) E mimetic peptides that stimulate cellular cholesterol efflux.
INTRODUCTION
HDL are thought to protect against arterial cholesterol deposition and risk of coronary events [1,2 && ]. This protection has been related, in part, to the activity of HDL and its apos mediating cellular cholesterol efflux and transporting cholesterol to the liver for excretion in feces, a process termed reverse cholesterol transport (RCT). The ATP-binding cassette transporter A1 (ABCA1) plays an essential role in this RCT process. ABCA1 belongs to a large family of ATP-binding cassette transporters. It is present at the plasma membrane of a wide-variety of cells where it mediates the efflux of cholesterol and phospholipid to extracellular apo acceptors, such as apoA-I, apoE, and small, lipid-poor HDL particles [3, 4] . In the liver and intestine, the formation of nascent HDL particles via ABCA1 is responsible for producing the bulk of plasma HDL. Locally within tissues, the lipid efflux function of ABCA1 is probably most important for preventing a build-up of excess cholesterol in cellular membranes. This cholesterol efflux function is vital to the prevention of degenerative disease, because cellular cholesterol accumulation can be cytotoxic, inflammatory, and alter the structure/function of the plasma membrane [5] [6] [7] . Nascent HDL particles generated via ABCA1 subsequently mediate cholesterol efflux via other cell-surface transporters such as ABCG1 [8, 9] . Thus the activity of ABCA1 is necessary for producing substrate particles that maintain cell lipid efflux responses, lipid homeostasis, and tissue integrity/function.
THERAPEUTIC ASPECTS-ATP-BINDING CASSETTE TRANSPORTER A1 AGONIST PEPTIDES
One viable approach for enhancing ABCA1 lipid efflux therapeutically invokes the use of small peptides based on HDL apos. To date, a number of apo mimetic peptides have been designed toward different HDL activities and molecular targets [10] [11] [12] [13] . Consequently, each exhibits its own unique formulation requirements and pharmacology. Very few of these peptides, however, target ABCA1 with high potency and selectivity [13] [14] [15] . ABCA1 transfers cellular lipid to lipid-poor acceptors and, thus, is unique compared with other lipid efflux transporters. Therefore, synthetic peptides can be optimized (i.e., screened) for cholesterol efflux activity, without having to formulate the peptides with phospholipid. My laboratory has found that a stable a-helical structure represents an important factor for creating peptides with potent ABCA1 cholesterol efflux activity [14] . This is also likely to be a key feature for improving the overall translatability of such peptides, as discussed below.
Peptide secondary structure and activity
The C-terminal lipid-binding domain of apoE has proven amenable to constructing small a-helical peptides for mediating cellular lipid efflux [15] . This domain represents the portion of apoE responsible for mediating ABCA1 cholesterol efflux with high affinity, and is enriched in salt-bridges that stabilize a-helix structure [3, 15] . Synthetic peptides based on this domain, such as ATI-5261, stimulate cellular cholesterol efflux similar to native apos. The potent activity of peptide ATI-5261 has been related to its unique ability to retain a-helical structure at very low concentrations, as individual peptide strands [16] . Figure 1 shows that retention of a-helix structure was attributed to key positively charged amino acids (R3, R14, and R23) located within ionic pairs (i þ 4) distributed down the length of the peptide. Ablation of these interactions using uncharged glutamine substitutions disrupted peptide secondary structure and activity upon dilution. It is widely known that a-helicity represents an important determinant for mediating ABCA1 lipid efflux; thus the ability of mimetic peptides to retain a-helix structure is likely to be critical in vivo, when the peptide distributes to various tissues and is extensively diluted following administration.
Solution properties
Mimetic peptides based on apos are often amphipathic with hydrophobic surfaces. This feature generally limits peptide solubility in the absence of lipid, since amphipathic peptides self-associate to shield hydrophobic residues from the water environment. Such an effect can be particularly troublesome for peptides that are relatively unstructured, since they tend to aggregate in a nonspecific manner to form precipitates. In contrast, peptides that we have engineered with high a-helix content self-associate in a specific manner to form well defined oligomers in solution, as peptide concentration increases [14] . Such behavior may be related to aspect of coiled-coil protein structure inherent to native a-helical segments of apoA-I and apoE that have been incorporated into the peptide design [17, 18] . These features include sites for putative charge interactions between adjacent a-helical strands to orient helix-helix contact, as well as a regular repeating pattern of hydrophobic residues (a-d motif) to facilitate self-association ( Fig. 2 ). In this manner, protein-like structures can be designed using motifs that facilitate inter-helical interactions [19] . As a result, exceedingly high stock concentrations of helical peptides can be achieved to afford convenient methods of administration, such as subcutaneous or intravenous injection [15] .
Safety features
Previous studies demonstrated that ATI-5261 displayed efficacy reducing substantial atherosclerosis in dietary and genetic mouse models of hyperlipidemia [15] . These effects were associated with a sustained increase in macrophage-specific RCT. Moreover, the lipid-free peptide was found to be KEY POINTS Small peptides that stimulate ABCA1 cholesterol efflux are being developed for therapeutic applications.
A lead peptide (CS6253) has emerged from optimization studies, which is highly safe and effective in mediating cellular cholesterol efflux.
Studies in mice indicate CS6253 exerts antiatherosclerosis and antidiabetic effects. effective, circumventing the need to formulate the peptide with phospholipid. Consequently, the lipidfree ATI-5261 peptide was considered a potential therapeutic candidate for entering into clinical development for the treatment of acute coronary syndrome and atherosclerosis.
Preclinical toxicology studies revealed, however, transient increases in plasma triglycerides using pharmacological doses of ATI-5261, similar to that seen with other HDL mimetic peptides [20] . In addition, injection of ATI-5261 at a dose 10-fold higher than that used to decrease atherosclerosis in mice-induced muscle toxicity ( Fig. 3 ). This was accompanied by an increase in the plasma concentration of muscle enzymes, including creatine phosphokinase, consistent with a cytotoxic response. Cytotoxic and triglycerides elevating effects were observed using ATI-5261 formulated with and without phospholipid, and in several animal species, such as mice, rats, rabbits, and cynomolgus monkeys (not shown).
Lead optimization studies were subsequently conducted to identify features of ATI-5261 that were responsible for the adverse side-effects. This was aided by detailed structural knowledge of the peptide ( Fig. 1) , which allowed manipulation of the amino acid composition in a targeted fashion without altering a-helicity and lipid efflux activity. Initial studies focused on amino acids thought to influence the interaction of amphipathic peptides with phospholipid bilayers, such as cationic and/or aromatic-residues [21, 22] . Peptide analogs were created with conservative amino acid substitutions to test each feature separately, and then both in combination. Replacement of phenylalanine residues with aliphatic leucine residues reduced a majority of the peptide cytotoxicity and $50% of the triglycerides elevations in plasma. Similar effects were noted upon replacement of interfacial arginine residues with uncharged citrulline. Use of both citrulline and leucine substitutions, simultaneously, in the same peptide eliminated the cytotoxic responses, as well as a majority ($90%) of the triglycerides elevating effects. The resulting peptide (CS6253) with both the citrulline and leucine substitutions stimulated ABCA1 lipid efflux with high potency and stabilized ABCA1 protein, similar to wild-type apoA-I ( Fig. 3) . These results were consistent with the ability of citrulline to maintain H-bonding and a-helicity, when used to replace arginine residues (R3 and R14). Collectively, the data indicated that the adverse side-effects of ATI-5261 were dependent on structural features linked to the class A a-helix motif. The presence of interfacial cationic residues together with aromatic phenylalanine residues in the same a-helix peptide were required to induce muscle toxicity and triglycerides elevations. However, the problematic (b) ATI-5263 is able to retain a high a-helical content as the peptide is diluted from 500 to 10 mg/ml (310-6 mM), under conditions that favor dissociation of oligomer forms to individual peptide strands [14, 16] . In contrast, the R ! Q variants of ATI-5261 failed to retain a-helix structure upon dilution, indicating salt bridge interactions were required to stabilize the secondary structure.
The high a-helical content observed with increasing peptide concentration is typically attributed to peptide self-association.
(c) Peptides with R ! Q substitutions are poor mediators of cholesterol efflux, as determined using J774 macrophages treated with cAMP to up-regulate ABCA1 [16] .
residues could be replaced with conservative substitutions without altering peptide secondary structure and activity. CS6253 was also found to reduce atherosclerotic plaque lesions in apoE knock-out mice in a manner analogous to that seen with ATI-5261 [23] .
POTENTIAL FOR THE TREATMENT OF DIABETES AND ALZHEIMER'S DISEASE
Recent studies indicate that HDL displays several distinct activities that modulate glucose homeostasis (i.e., enhance insulin secretion and glucose tolerance), and that mimetic peptides can recapitulate some of these effects [24] [25] [26] [27] [28] [29] [30] [31] [32] . Interestingly, a number of these reported functions involve ABCA1, and still others can be viewed as supporting ABCA1 activity. The latter includes activities of HDL to increase glucose uptake and utilization by cells, improve mitochondrial energy production, and control ABCA1 protein concentration via posttranslational mechanisms. Genetic manipulation of apoA-I in transgenic mice has revealed a novel role of HDL in stimulating glucose oxidation and mitochondrial respiration in a   2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24 vivo [33] . Increased mitochondrial respiration and ATP production are expected to have a positive impact on ABCA1 activity and other cell surface transporters that require energy for activity. Such effects would be considered beneficial to optimize lipid efflux responses and disease prevention [34] . Mitochondrial function has the potential to modulate ABCA1 protein at several levels. This includes regulation of ABCA1 gene expression via production of oxysterols [35 && , 36, 37] . Moreover, increased permeabilization of the mitochondrial outer membrane during disease is often associated with the release of caspases and reactive oxygen species into the cytosol. Caspases can degrade calpastatin, an endogenous inhibitor of calpain [38] . As a result, calpain activity in cells is likely to increase with mitochondrial dysfunction and/or disease to facilitate ABCA1 degradation. Thus it is reasonable to speculate that HDL and its mimetic peptides may protect ABCA1 from degradation by improving mitochondrial function and modulating the calpastatin-calpain system. HDL apos are also known to stabilize ABCA1 concentration in membranes via cell-surface interactions that protect the transporter from degradation.
Optimizing ABCA1 lipid efflux activity may also be an important factor in protecting against Alzheimer's disease [39] [40] [41] . In the brain, ABCA1 is thought to facilitate the lipidation of apoE and clearance of b-amyloid [42, 43] . In this manner, ABCA1 may protect against cognitive decline, particularly in the context of the apoE4 phenotype [43]. Thus targeting ABCA1 therapeutically with a small peptide may be useful for the treatment of human Alzheimer's disease associated with apoE4.
CONCLUSION
HDL mimetic peptides based on the C-terminal domain of apoE have been developed that target ABCA1 for the treatment of disease. A lead compound, CS6253, has emerged from preclinical optimization studies that is highly safe, mediates ABCA1 cholesterol efflux with high potency, stabilizes ABCA1 cell-surface concentration, and reduces substantial atherosclerosis in mouse models under conditions of excess lipid burden. The importance of ABCA1 in different tissues further suggests CS6253 may be useful therapeutically to combat diabetes and Alzheimer's disease. Future studies investigating the ability of CS6253 to improve glucose homeostasis, mitochondrial function, and inflammation are warranted. The role of specific apoE isoforms improving glucose utilization and preserving mitochondrial function in the aging brain also represent potentially interesting areas of investigation, particularly in the context of dementia.
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